144 related articles for article (PubMed ID: 32478230)
1. Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches.
Sato T; Sekimata K; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Tanaka A; Shirouzu M; Yokoyama S; Hashizume Y; Miyazono K; Koyama H; Honma T
ACS Omega; 2020 May; 5(20):11411-11423. PubMed ID: 32478230
[TBL] [Abstract][Full Text] [Related]
2. Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H).
Sekimata K; Sato T; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Honma T; Tanaka A; Shirouzu M; Yokoyama S; Miyazono K; Hashizume Y; Koyama H
Chem Pharm Bull (Tokyo); 2019; 67(3):224-235. PubMed ID: 30828000
[TBL] [Abstract][Full Text] [Related]
3. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Davis AJ; Brooijmans N; Brubaker JD; Stevison F; LaBranche TP; Albayya F; Fleming P; Hodous BL; Kim JL; Kim S; Lobbardi R; Palmer M; Sheets MP; Vassiliadis J; Wang R; Williams BD; Wilson D; Xu L; Zhu XJ; Bouchard K; Hunter JW; Graul C; Greenblatt E; Hussein A; Lyon M; Russo J; Stewart R; Dorsch M; Guzi TJ; Kadambi V; Lengauer C; Garner AP
Sci Transl Med; 2024 May; 16(749):eabp8334. PubMed ID: 38809966
[TBL] [Abstract][Full Text] [Related]
4. Activation of G
Ebner JK; König GM; Kostenis E; Siegert P; Aktories K; Orth JHC
Bone; 2019 Oct; 127():592-601. PubMed ID: 31376533
[TBL] [Abstract][Full Text] [Related]
5. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
[TBL] [Abstract][Full Text] [Related]
7. The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A.
Szilágyi SS; Burdzinski W; Jatzlau J; Ehrlich M; Knaus P; Henis YI
Cells; 2024 Jan; 13(3):. PubMed ID: 38334613
[TBL] [Abstract][Full Text] [Related]
8. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
[TBL] [Abstract][Full Text] [Related]
9. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
[TBL] [Abstract][Full Text] [Related]
10. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
11. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.
Le VQ; Wharton KA
Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087
[TBL] [Abstract][Full Text] [Related]
12. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
Takahashi M; Katagiri T; Furuya H; Hohjoh H
Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
[TBL] [Abstract][Full Text] [Related]
13. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Williams E; Bullock AN
Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
[TBL] [Abstract][Full Text] [Related]
15. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
[TBL] [Abstract][Full Text] [Related]
16. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Lin H; Shi F; Gao J; Hua P
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
[TBL] [Abstract][Full Text] [Related]
17. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
18. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
[TBL] [Abstract][Full Text] [Related]
20. An Activin Receptor IA/Activin-Like Kinase-2 (R206H) Mutation in Fibrodysplasia Ossificans Progressiva.
Herrera-Esparza R; Pacheco-Tovar D; Bollain-Y-Goytia JJ; Torres Del Muro F; Ramírez-Sandoval R; Pacheco-Tovar MG; Castañeda-Ureña M; Avalos-Díaz E
Case Rep Genet; 2013; 2013():260371. PubMed ID: 23653868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
